China Meheco Group Co Ltd
SSE:600056
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
C
|
China Meheco Group Co Ltd
SSE:600056
|
16.2B CNY |
Loading...
|
|
| JP |
|
Mitsubishi Corp
TSE:8058
|
17.4T JPY |
Loading...
|
|
| JP |
|
Itochu Corp
TSE:8001
|
15.8T JPY |
Loading...
|
|
| JP |
|
Mitsui & Co Ltd
TSE:8031
|
14.7T JPY |
Loading...
|
|
| JP |
|
Marubeni Corp
TSE:8002
|
8.9T JPY |
Loading...
|
|
| US |
|
W W Grainger Inc
NYSE:GWW
|
56.9B USD |
Loading...
|
|
| US |
W
|
WW Grainger Inc
XMUN:GWW
|
47.9B EUR |
Loading...
|
|
| US |
|
Fastenal Co
NASDAQ:FAST
|
54.3B USD |
Loading...
|
|
| US |
|
United Rentals Inc
NYSE:URI
|
53.1B USD |
Loading...
|
|
| US |
|
Ferguson Enterprises Inc
NYSE:FERG
|
50B USD |
Loading...
|
|
| JP |
|
Sumitomo Corp
TSE:8053
|
7.2T JPY |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
China Meheco Group Co Ltd
Glance View
China Meheco Group Co., Ltd., established in 1984, stands as a prominent player in the Chinese pharmaceutical and healthcare sector. As the company evolved over the decades, it navigated the complex Chinese market by strategically positioning itself across the entire pharmaceutical value chain. This involved investing heavily in research and development, securing partnerships with both domestic and international pharmaceutical companies, and streamlining its distribution network to enhance efficiency. Such endeavors have enabled China Meheco to develop and distribute a wide range of medical products, including active pharmaceutical ingredients, finished drugs, medical devices, and traditional Chinese medicines. The company leverages its robust R&D capabilities to continually bring innovative products to market, which has been a significant source of its revenue. China Meheco's business model thrives on its expansive distribution network and strategic collaborations. By aligning with global pharmaceutical giants, the company not only gains access to cutting-edge technologies and advanced formulations but also expands its market reach beyond China. This dual strategy of innovation and partnership ensures a steady flow of products that cater to diverse healthcare needs. Furthermore, China Meheco capitalizes on its local expertise and deep understanding of regulatory frameworks, allowing it to maneuver efficiently within China's complex healthcare landscape. This approach underpins its ability to capture substantial market share in a competitive industry, driving profitability and positioning the company as a key player in the global pharmaceutical arena.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for China Meheco Group Co Ltd is 1.6%, which is below its 3-year median of 1.9%.
Over the last 3 years, China Meheco Group Co Ltd’s Net Margin has increased from 1.6% to 1.6%. During this period, it reached a low of 1.4% on Sep 30, 2023 and a high of 2.7% on Dec 31, 2023.